Zynex Medical Electrotherapy Pain Management and Growth Strategy

Adjusted EBITDA Net income Depreciation and Amortization Stock-based compensation expense Interest expense and other, net Income tax expense Adjusted EBITDA % of Net Revenue $ $ Adjusted EBITDA: Net income $ Depreciation and Amortization Stock-based compensation expense Interest expense and other, net Income tax expense Adjusted EBITDA % of Net Revenue EBITDA Reconciliation - 2020 For the Three Months Ended March 31, 2020 2019 Adjusted EBITDA 2,937 $ 2,350 Net income 68 66 Depreciation and Amortization 497 139 Stock-based compensation expense 4 (880) Interest expense and other, net (483) 786 Income tax expense 3,023 $ 2,461 Adjusted EBITDA 20% 27% % of Net Revenue For the Three Months Ended September 30, 2020 2019 $ $ For the Three Months Ended June 30, 2020 3,017 $ 97 579 5 1,063 4,761 $ 25% 2019 2,162 76 158 422 2,818 27% For the Three Months Ended December 31, 2020 2019 1,788 $ 2,947 272 60 875 264 82 6 428 778 $ 3,445 $ 4,055 13% 29% Adjusted EBITDA: 1,333 $ 2,033 Net income $ 305 50 Depreciation and Amortization* 730 259 Stock-based compensation expense 5 71 463 $ 2,444 $ Interest expense and other, net Income tax expense 2,805 Adjusted EBITDA 12% 24% % of Net Revenue ZYNEX 25 MEDICAL"

View entire presentation